Sylentis Aims to Begin Phase I Study of Glaucoma Drug in September

Aug 20, 2009

Premium

Spanish RNAi drug shop Sylentis expects to dose the first patient in a phase I study of its glaucoma-associated ocular hypertension drug SYL040012 in Spain around the end of September, a company official confirmed to RNAi News this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Teeny Tiny DNA Robot

Popular Mechanics reports that Caltech researchers have built a prototype nanobot using DNA.

New Siblings

The Sacramento Bee writes that direct-to-consumer genetic testing connected a woman to sperm donor-conceived half siblings.

This Week in PLOS

In PLOS this week: gene expression catalog for sheep, viral diversity among respiratory samples from camels, and more.

Featured White Papers

High Throughput RT-qPCR for Gene Expression Analysis

Main menu